InMed Pharmaceuticals Inc trades with the ticker In on the TSX and is in the industry.
Overview
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Looking to invest in InMed Pharmaceuticals Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.
Table of Contents
show
In.TO Stock Price and Key Stats
ETF Key Stats
Exchange: TSX
Market Cap : $33.732MM
PE Ratio:
Price: #N/A (Updated: 3/12/2024 0:47:16)
InMed Pharmaceuticals Inc (In) vs Competitors in
Lets see how In.TO stacks up against others in the asset management industry. We have identified its main peers as:Kinder Morgan Canada Limited, Storm Resources Ltd, UrtheCast Corp, World Financial Split Corp
.Industry information unavailable.
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield
Comparisons within
- InMed Pharmaceuticals Inc (In) vs Kinder Morgan Canada Limited (KML)
- KML has higher EPS (0.392 vs -0.077). KML has higher dividend yield (4.4% vs 0.0%). In has a P/E under 0, indicating KML (P/E 24.048) is in a better position.
- InMed Pharmaceuticals Inc (In) vs Storm Resources Ltd (SRX)
- SRX has higher EPS (0.068 vs -0.077). SRX has higher dividend yield (0.0% vs 0.0%). In has a P/E under 0, indicating SRX (P/E 92.206) is in a better position.
- InMed Pharmaceuticals Inc (In) vs UrtheCast Corp (UR)
- In has higher EPS (-0.077 vs -0.546). UR has higher dividend yield (0.0% vs 0.0%). UR and In both have P/E’s under 0.
- InMed Pharmaceuticals Inc (In) vs World Financial Split Corp (WFS)
- In has higher EPS (-0.077 vs -2.142). In provides dividends, while WFS does not. WFS and In both have P/E’s under 0.
Our Recommendation: Hold
Shows positive EPS growth from this year to next, suggesting improving profitability. Features a lower EV/EBITDA ratio (0.00) than the industry average (4.80), indicating attractive valuation.
How to Buy In stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:| Image | Product Title | Features | Price |
|---|---|---|---|
Editor's Choice  |
| Get $25 Signup Bonus | |
Reliable Pick  |
| Get $50 Free Stock Trades |
